Products
Online Inquiry
kira6
Cat. No.:
OB0225WX-2774
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
kira6 is a potent type II kinase inhibitor of IRE1-alpha (IC50: 0.6 micromolar) that effectively blocks its oligomerization and subsequent RNA cleavage activities.
Synonym:
1589527-65-0; 1-(4-(8-amino-3-(tert-butyl)imidazo[1,5-a]pyrazin-1-yl)naphthalen-1-yl)-3-(3-(trifluoromethyl)phenyl)urea; Urea, N-[4-[8-amino-3-(1,1-dimethylethyl)imidazo[1,5-a]pyrazin-1-yl]-1-naphthalenyl]-N'-[3-(trifluoromethyl)phenyl]-; 1-(4-(8-Amino-3-tert-butylimidazo[1,5-a]pyrazin-1-yl)naphthalen-1-yl)-3-(3-(trifluoromethyl)phenyl)urea; 1-[4-(8-amino-3-tert-butylimidazo[1,5-a]pyrazin-1-yl)naphthalen-1-yl]-3-[3-(trifluoromethyl)phenyl]urea; 3-(4-{8-amino-3-tert-butylimidazo[1,5-a]pyrazin-1-yl}naphthalen-1-yl)-1-[3-(trifluoromethyl)phenyl]urea; 3-(4-{8-amino-3-tert-butyl-1H,7H-imidazo[1,5-a]pyrazin-1-ylidene}-1,4-dihydronaphthalen-1-ylidene)-1-[3-(trifluoromethyl)phenyl]urea
CAS No.:
1589527-65-0
Compound CID:
73425700
Formula:
C28H25F3N6
Formula Weight:
518.53
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
kira6 is used in proteostasis research as a potent and selective IRE1 alpha inhibitor to investigate the modulation of the unfolded protein response (UPR) and its role in preventing ER stress-induced apoptosis in degenerative diseases.
Library Information
Target:
IRE1
Receptor:
IRE1α
Pathways:
ER stress & UPR
Plate Number:
L6700-11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
60 mg/mL; 115.71 mM
Ethanol Max Solubility:
60 mg/mL
ALogP:
5.531
HBA_Count:
3
HBD_Count:
3
Rotatable Bond:
5